Immunization against bovine papillomavirus infection

Area of Science:

• Veterinary Virology
• Molecular Biology
• Immunology

Background:

• Bovine papillomavirus type 1 (BPV-1) is a significant veterinary pathogen.
• The L1 and L2 open reading frames are key components of the BPV-1 genome.
• Understanding BPV-1 protein function is crucial for developing effective vaccines.

Purpose of the Study:

• To molecularly clone and express BPV-1 L1 and L2 proteins in Escherichia coli.
• To evaluate the immunogenicity and protective efficacy of E. coli-derived BPV-1 proteins.
• To assess the potential of these proteins as vaccine candidates against BPV-1.

Main Methods:

• Molecular cloning of BPV-1 L1 and L2 genes into E. coli expression vectors.
• Production and purification of recombinant L1 and L2 proteins.
• Generation of antisera against the recombinant proteins.
• Enzyme-linked immunosorbent assays (ELISA) and immunoprecipitation to detect BPV-1 specific antibodies.
• In vitro neutralization assays using mouse C127 cells.
• Vaccination of calves with E. coli-derived L1 protein followed by BPV-1 challenge.

Main Results:

• Successfully expressed BPV-1 L1 and L2 proteins in E. coli.
• Antisera against E. coli-derived L1 and L2 proteins recognized BPV-1.
• Antisera against L1 protein demonstrated consistent neutralization of BPV-1-induced cell transformation.
• Vaccination of calves with E. coli-derived L1 protein conferred protection against BPV-1 challenge.

Conclusions:

• Recombinant BPV-1 L1 protein expressed in E. coli is immunogenic and capable of inducing protective immunity.
• The L1 protein is a promising candidate for a BPV-1 vaccine.
• This study provides a foundation for developing subunit vaccines against papillomaviruses.